What is the recommended treatment protocol for secukinumab (Secukinumab) in patients with moderate-to-severe plaque psoriasis, including dosing schedule, weight‑based dosing, infection screening, pregnancy considerations, and management of inadequate response?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Secukinumab Treatment Protocol for Psoriasis

For adults with moderate-to-severe plaque psoriasis, initiate secukinumab at 300 mg subcutaneously at weeks 0,1,2,3, and 4, followed by 300 mg every 4 weeks as maintenance therapy. 1

Dosing Schedule

Standard Adult Regimen (Strength of Recommendation: A)

Loading Phase:

  • 300 mg subcutaneous injection at weeks 0,1,2,3, and 4 1

Maintenance Phase:

  • 300 mg every 4 weeks starting at week 8 1

Critical Dosing Note: The 300 mg dose is significantly more effective than 150 mg and should be the standard dose. While 150 mg may be acceptable for some patients, the higher dose achieves superior PASI 90 responses (79% vs 57.6% compared to ustekinumab at week 16) with equivalent safety 1. Do not use "as-needed" dosing after week 12—this approach is less effective than continuous every-4-week dosing 1.

Weight-Based Considerations

Body weight ≥90 kg with inadequate response at week 24:

  • Consider intensifying to 300 mg every 2 weeks if PASI 90 not achieved 2
  • Standard every-4-week dosing remains optimal for most patients, but heavier patients may benefit from dose intensification 2

Body weight-specific optimization:

  • Patients 70-110 kg: maintain 300 mg every 4 weeks 3
  • Patients ≥120 kg: consider 300 mg every 3 weeks 3
  • Patients <70 kg: standard dosing remains appropriate 3

Pre-Treatment Screening

Infection Screening (Required)

Tuberculosis:

  • PPD or interferon-gamma release assay
  • Chest radiograph if indicated
  • Do not initiate with active TB—treat latent TB before starting secukinumab 1

Hepatitis B:

  • Screen for HBsAg and anti-HBc
  • Relative contraindication if untreated hepatitis B infection 1

Active Infections:

  • Absolute contraindication during active infection or sepsis
  • Consult infectious disease specialist if considering initiation during active infection 1
  • Temporarily discontinue for febrile illness requiring treatment; restart after full resolution and completion of antibiotics 1

Baseline Laboratory Assessment

  • Complete blood count (CBC)
  • Complete metabolic panel (CMP)
  • Consider baseline inflammatory markers 1

Pregnancy and Contraception

Women of childbearing potential:

  • Safety during pregnancy is uncertain—avoid use during pregnancy unless clearly necessary 1
  • Discuss contraception and family planning before initiating therapy

Men attempting conception:

  • Secukinumab is acceptable for men attempting conception with their partner 1

Lactation:

  • Safety during lactation is uncertain 1

Management of Inadequate Response

Primary Failure (Week 12-24 Assessment)

If PASI 75 not achieved by week 12-16:

  1. Verify adherence to dosing schedule
  2. Consider body weight (if ≥90 kg, intensify to every 2 weeks) 2
  3. Optimize adjunctive topical therapy
  4. If no response by week 24, switch to alternative biologic 4

Secondary Failure (Loss of Response)

If initial response followed by loss of efficacy:

  1. Assess for:
    • Medication adherence
    • Weight gain (may require dose adjustment)
    • Concurrent infections or inflammatory conditions
  2. Consider dose intensification if appropriate
  3. Switch to alternative biologic if optimization fails 4

Dose Escalation Strategy (if funded and feasible)

  • From 300 mg every 4 weeks → 300 mg every 2 weeks
  • This is off-label but may be considered for inadequate primary response, particularly in obese patients 4
  • Associated with increased infection risk 4

Reinitiation After Treatment Interruption

If treatment interrupted:

  • Repeat loading doses if:
    • Patient is experiencing disease flare, AND/OR
    • More than 3-4 half-lives have passed since previous dose (approximately 12-16 weeks) 1
  • Otherwise, resume maintenance dosing schedule

Special Psoriasis Manifestations

Secukinumab is effective for:

  • Nail psoriasis (Strength A) 1
  • Palmoplantar plaque psoriasis (Strength A) 1
  • Scalp psoriasis (Strength B) 1
  • Palmoplantar pustulosis (Strength B) 1
  • Erythrodermic psoriasis (Strength C) 1
  • Psoriasis with psoriatic arthritis (Strength A) 1

Contraindications

Absolute Contraindications

  • History of allergic reaction to secukinumab or vehicle 1

Relative Contraindications

  • Untreated hepatitis B infection 1
  • History of lymphoreticular malignancy 1
  • Active infection or sepsis 1
  • Inflammatory bowel disease (use with caution—may exacerbate Crohn's disease) 5

Safety Monitoring

Common Adverse Events

  • Nasopharyngitis (most common)
  • Candida infections (mild-to-moderate oral or genital candidiasis may occur) 5
  • Reversible transient neutropenia 5

Ongoing Monitoring

  • Monitor for signs of infection at each visit
  • Temporarily discontinue for febrile illness requiring treatment 1
  • Neutralizing antibodies are rare (<0.4%) and not associated with loss of efficacy 1

Vaccination Considerations

Non-live vaccines:

  • Can be administered during treatment
  • Antibody responses are preserved 6

Live vaccines:

  • Avoid during treatment (standard precaution for immunosuppressive therapy)

Combination Therapy

Topical or systemic combinations:

  • No published safety concerns with combination therapy
  • Combination with topical or systemic therapies is considered safe 1

Pediatric Dosing (Age ≥6 years)

Weight-based dosing:

  • <25 kg: 75 mg
  • 25 to <50 kg: 75 mg
  • ≥50 kg: 150 mg
  • Same loading schedule (weeks 0,1,2,3,4) then every 4 weeks 6, 7

Related Questions

For a patient with plaque psoriasis living abroad, can secukinumab be initiated with a single monthly dose instead of the recommended weekly loading schedule?
What is the recommended dosing regimen for a 27-year-old male with moderate-to-severe plaque psoriasis?
What additional baseline investigations are required before initiating secukinumab (Cosentyx) in a 10‑year‑old child with severe psoriasis vulgaris, beyond tuberculin skin test or chest radiograph, hepatitis B surface antigen and core antibody, hepatitis C antibody, HIV 1/2 antibody, complete blood count, renal and liver function tests, lipid profile, and review for inflammatory bowel disease symptoms?
What is a detailed prescription for a patient with moderate-to-severe plaque psoriasis, including biologic (Secukinumab) dosing, dispensing, storage, adjunctive topical calcipotriene/betamethasone therapy, baseline laboratory screening, monitoring schedule, and an alternative biologic (Guselkumab) if biologic therapy is contraindicated?
What are the latest evidence updates on the side effects of secukinumab (Cosentyx) in children aged 10 years and older?
What is the physiology of evoked potentials under inhalational anesthetics?
What causes a ringing sensation (tinnitus) after using earphones?
What is the body mass index (BMI) for a person who is 5 feet 6 inches tall and weighs 88 kilograms?
What treatment options are recommended for a patient with noise‑induced tinnitus who uses earphones at high volume for long periods?
What are the clinical differences between Hodgkin lymphoma and non-Hodgkin lymphoma?
What is the recommended approach to assess stability and manage a proximal interphalangeal (PIP) joint fracture‑dislocation, including indications for a hemi‑hamate osteochondral autograft?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.